Invited Article: Functional imaging in Parkinson disease

Neurology

Volumn 70, Issue 16 PART 2, 2008, Pages 1478-1488

  Nandhagopal, R ^a   McKeown, Martin J ^a   Stoessl, A Jon ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROTETRABENAZINE C 11; FLUORODEOXYGLUCOSE F 18; LEVODOPA; METHAMPHETAMINE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NEUROTRANSMITTER; TRACER; UNCLASSIFIED DRUG; VERAPAMIL C 11;

ARTICLE; BRAIN BLOOD FLOW; BRAIN DEPTH STIMULATION; BRAIN METABOLISM; COGNITION; COGNITIVE DEFECT; DISEASE COURSE; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DYSKINESIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMAGING; INFLAMMATION; MENTAL DISEASE; MOOD CHANGE; MOTOR CONTROL; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NERVE CELL; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; OUTCOME ASSESSMENT; OXYGEN BLOOD LEVEL; PARKINSON DISEASE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REGULATORY MECHANISM; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOMATOLOGY; TREATMENT RESPONSE; ANIMAL; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; HUMANS; MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 42049109275     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000310432.92489.90     Document Type: Review

References (12)

1. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000;47:493-503.
2. Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006;59:852-858.
3. de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001;293:1164-1166.
4. Thobois S, Dominey P, Fraix V, et al. Effects of subthalamic nucleus stimulation on actual and imagined movement in Parkinson's disease: a PET study. J Neurol 2002;249:1689-1698.
5. Brefel-Courbon C, Payoux P, Thalamas C, et al. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 2005;20:1557-1563.
6. Adams JR, van Netten H, Schulzer M, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005;128(Pt 12):2777-2785.
7. Buhmann C, Binkofski F, Klein C, et al. Motor reorganization in asymptomatic carriers of a single mutant Parkin allele: a human model for presymptomatic parkinsonism. Brain 2005;128(Pt 10):2281-2290.
8. Asanuma K, Tang C, Ma Y, et al. Network modulation in the treatment of Parkinson's disease. Brain 2006;129(Pt 10):2667-2678.
9. Sossi V, de la Fuente-Fernandez R, Schulzer M, Adams J, Stoessl J. Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. Brain 2006;129(Pt 4):1050-1058.
10. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005 128(Pt 6):1314-1322.
11. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003;60:1745-1748.
12. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-414.